Literature DB >> 17304444

Prolonged QT interval and torsades de pointes associated with atazanavir therapy.

Tam Ly1, Maria Elena Ruiz.   

Abstract

We report, to our knowledge, the first documented case of torsades de pointes associated with atazanavir therapy. This case serves to highlight the need to monitor patients receiving atazanavir therapy who have risk factors for QT interval prolongation, such as female sex, bradycardia, electrolyte abnormalities, congestive heart failure, and a baseline prolonged QT interval.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17304444     DOI： 10.1086/511875

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

1.  Prolongation of the QTc interval in HIV-infected individuals compared to the general population.

Authors:  Nico Reinsch; Marina Arendt; Marie Henrike Geisel; Christina Schulze; Volker Holzendorf; Anna Warnke; Till Neumann; Norbert H Brockmeyer; Dirk Schadendorf; Lewin Eisele; Raimund Erbel; Susanne Moebus; Karl-Heinz Jöckel; Stefan Esser
Journal:  Infection       Date:  2017-08-03       Impact factor: 3.553

2.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

3.  QT dispersion in HIV-infected patients receiving combined antiretroviral therapy.

Authors:  Wanwarang Wongcharoen; Somkhuan Suaklin; Nualnit Tantisirivit; Arintaya Phrommintikul; Nipon Chattipakorn
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-21       Impact factor: 1.468

Review 4.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

Review 5.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

6.  Acquired Long QT Syndrome and Torsade de Pointes Associated with HIV Infection.

Authors:  Alexander Shimabukuro-Vornhagen; Jan Rybniker; Shahram Zoghi; Gerd Faetkenheuer; Guido Michels; Erland Erdmann; Michael von Bergwelt-Baildon; Matthias Kochanek
Journal:  Case Rep Med       Date:  2010-08-23

7.  Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.

Authors:  Anchalee Avihingsanon; Stephen J Kerr; Baralee Punyawudho; Jasper van der Lugt; Meena Gorowara; Jintanat Ananworanich; Joep M A Lange; David A Cooper; Praphan Phanuphak; David M Burger; Kiat Ruxrungtham
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-02       Impact factor: 2.205

8.  Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.

Authors:  Elsayed Z Soliman; Jens D Lundgren; Mollie P Roediger; Daniel A Duprez; Zelalem Temesgen; Markus Bickel; Judith C Shlay; Charurut Somboonwit; Peter Reiss; James H Stein; James D Neaton
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

9.  In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.

Authors:  Ehab Al-Moubarak; Mohsen Sharifi; Jules C Hancox
Journal:  Front Cardiovasc Med       Date:  2021-05-04

10.  QTc interval prolongation in HIV-infected patients: a case-control study by 24-hour Holter ECG recording.

Authors:  Alessandra Fiorentini; Nicola Petrosillo; Angelo Di Stefano; Stefania Cicalini; Laura Borgognoni; Evangelo Boumis; Luigi Tubani; Pierangelo Chinello
Journal:  BMC Cardiovasc Disord       Date:  2012-12-23       Impact factor: 2.298
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.